Introduction
============

Several randomized prospective studies showed some beneficial protective effects of exogenous human purified C1-esterase inhibitor (C1INH) in patients with sepsis \[[@B1],[@B2]\]. Our purpose was to evaluate influence of systemic inflammation on the pharmacokinetic--pharmacodynamic of C1INH in patients with sepsis.

Methods
=======

C1INH (Bicizar^®^; BioGenius LLC, Russia) was administered at the total dosage of 12,000 U in 48 hours (scheme of infusion: 6,000 U, 3,000 U, 2,000 U, 1,000 U every 12 hours) to 13 patients meeting ACCP/SCCM sepsis criteria during the first 24 hours after hospitalization. C1INH activity and C3, C4, IL-6 and procalcitonin levels were measured at baseline, 5 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 10 hours after C1INH intravenous infusion. The ratio of *C*~initial~to *C*~max\ 0--10\ hours~reflected changes in C1INH activity after 6,000 U infusion. AUC 0--10 hours was calculated after correction of the C1INH activity--time curve to baseline.

Results
=======

The median C1INH maximal shift after the first infusion was 55% (38--75%), as reflected by *C*~initial~/*C*~max\ 0--10\ hours~. The calculated AUC 0--10 hours was 8.8 U-hours/ml (4.6--14.5 U-hours/ml). In patients with lower C~initial~1.69 U/ml (0.96--2.65 U/ml), levels of C3 (*r*= 0.69, *P*\< 0.01) and C4 (*r*= 0.67, *P*\< 0.05) at baseline were likely to be decreased. A direct correlation between C3 level and *C*~initial~/C~max\ 0--10\ hours~(*r*= 0.49, *P*\< 0.05) as well as inverse correlation with AUC 0--10 hours (*r*= -0.613, *P*\< 0.05) were found. The significant correlation of *C*~initial~/C~max\ 0--10\ hours~with the baseline procalcitonin was also observed (*r*= 0.57, *P*\< 0.05).

Conclusion
==========

The shift in C1INH activity after 6,000 U infusion of purified protein was likely to be connected with baseline compliment activity in sepsis. Initial C3 and C4 depletion was associated with increased C1INH activity. The pharmacokinetic--pharmacodynamic profile of human purified C1INH might also be influenced by the severity of systemic inflammatory response. These factors could have some implication in the dosage-adjustment strategy.
